A Phase 3 interventional study of Vedolizumab 300 mg IV and Placebo IV in Colitis, Ulcerative, sponsored by Takeda. Completed at 174 sites in 31 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-25.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 9th largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 3, and was the 9th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 383 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 10th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2015, is one of 21 in phase 3, and was the 20th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) maintenance treatment on clinical remission at Week 52 in participants with moderately to severely active ulcerative colitis (UC) who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.
The drug being tested in this study is called vedolizumab subcutaneous (vedolizumab SC). Vedolizumab SC is being tested to treat people who have moderate to severely active ulcerative colitis. This study will look at clinical remission as well as mucosal healing, durable clinical response, durable clinical remission, and corticosteroid free remission in participants with UC who receive vedolizumab SC maintenance therapy after having achieved a clinical response to vedolizumab IV induction therapy.
The study enrolled 383 patients. All participants will enter into a 6-week Induction Phase where they will be administered open-label vedolizumab IV 300 mg via intravenous infusion (IV) at Week 0 (Day 1) and Week 2 (Day 15), and will then be assessed for a clinical response at Week 6. Participants who achieve a clinical response at Week 6 will be randomly assigned to one of the three treatment groups:
Vedolizumab SC 108 mg Q2W and Placebo IV Q8W Vedolizumab IV 300 mg Q8W and Placebo SC Q2W Placebo SC Q2W and Placebo IV Q8W
Participants who do not achieve a clinical response at Week 6 will not be randomized in to the Maintenance Period, and will receive a third infusion of vedolizumab IV 300 mg at Week 6.
This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 71 weeks (up to 4 weeks of screening, 52 weeks of treatment and 18 weeks of safety follow-up). Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.
After the Week 52 assessments, participants meeting protocol-defined criteria were eligible to enroll in Study MLN0002SC-3030 (NCT02620046; Long-term Safety) to receive open-label vedolizumab treatment. Participants who withdrew early (prior to Week 52) due to sustained nonresponse, disease worsening, or the need for rescue medications may also have been eligible for Study MLN0002SC-3030. Participants who did not enroll into Study MLN0002SC-3030 were to complete a final on-study safety assessment at Week 68 (or final safety visit 18 weeks after the last dose) in the Maintenance Phase of Study MLN0002SC-3027.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
Drug: Vedolizumab 300 mg IV · Drug: Placebo IV · Drug: Vedolizumab 108 mg SC
Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
Drug: Vedolizumab 300 mg IV · Drug: Placebo SC
Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
Drug: Vedolizumab 300 mg IV · Drug: Placebo IV · Drug: Placebo SC
Vedolizumab intravenous infusion
Vedolizumab intravenous infusion placebo
Vedolizumab subcutaneous injection
Vedolizumab subcutaneous injection placebo
Percentage of Participants Achieving Clinical Remission at Week 52
Clinical remission is defined as a complete Mayo score ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 52
Percentage of Participants Achieving Mucosal Healing at Week 52
Mucosal healing is defined as Mayo endoscopic subscore ≤1 point. The findings on endoscopy scale ranges from 0 to 3, where 0=normal or inactive disease 1=mild disease (erythema, decreased vascular pattern, mild friability) 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions) 3=severe disease (spontaneous bleeding, ulceration).
Time frame: Week 52
Percentage of Participants Achieving Durable Clinical Response at Week 6 and Week 52
Durable clinical response is defined as clinical response at both Weeks 6 and 52, where clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Baseline, Weeks 6 and 52
Percentage of Participants Achieving Durable Clinical Remission at Week 6 and Week 52
Durable clinical remission is defined as clinical remission at both Weeks 6 and 52. Clinical remission is defined as a complete Mayo score of less than or equal to (≤) 2 points and no individual subscore greater than (\>) 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Weeks 6 and 52
Percentage of Participants Achieving Corticosteroid-free Remission at Week 52
Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 52
Participants took part in the study at one hundred forty-one investigative sites in North America, South America, Western/Northern Europe, Central Europe, Eastern Europe and Africa/Asia/Australia from 18-Dec-2015 to 21-Aug-2018.
| Milestone | Open-Label Induction Phase: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|---|
| Started | 383 | 0 | 0 | 0 |
| Completed | 353 | 0 | 0 | 0 |
| Not completed | 30 | 0 | 0 | 0 |
| Withdrew: Pretreatment event/adverse event | 9 | 0 | 0 | 0 |
| Withdrew: Significant protocol deviation | 4 | 0 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 5 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 9 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 0 | 0 | 0 |
| Milestone | Open-Label Induction Phase: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|---|
| Started | 0 | 56 | 106 | 54 |
| Completed | 0 | 20 | 75 | 39 |
| Not completed | 0 | 36 | 31 | 15 |
| Withdrew: Lack of efficacy | 0 | 29 | 18 | 6 |
| Withdrew: Pretreatment event/adverse event | 0 | 5 | 5 | 2 |
| Withdrew: Significant protocol deviation | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Voluntary withdrawal | 0 | 1 | 2 | 5 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 4 | 0 |
Clinical remission is defined as a complete Mayo score ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 52 | 14.3 (6.4 to 26.2) | 46.2 (36.5 to 56.2) | 42.6 (29.2 to 56.8) |
Mucosal healing is defined as Mayo endoscopic subscore ≤1 point. The findings on endoscopy scale ranges from 0 to 3, where 0=normal or inactive disease 1=mild disease (erythema, decreased vascular pattern, mild friability) 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions) 3=severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|
| Percentage of Participants Achieving Mucosal Healing at Week 52 | 21.4 (11.6 to 34.4) | 56.6 (46.6 to 66.2) | 53.7 (39.6 to 67.4) |
Durable clinical response is defined as clinical response at both Weeks 6 and 52, where clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|
| Percentage of Participants Achieving Durable Clinical Response at Week 6 and Week 52 | 28.6 (17.3 to 42.2) | 64.2 (54.3 to 73.2) | 72.2 (58.4 to 83.5) |
Durable clinical remission is defined as clinical remission at both Weeks 6 and 52. Clinical remission is defined as a complete Mayo score of less than or equal to (≤) 2 points and no individual subscore greater than (\>) 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|
| Percentage of Participants Achieving Durable Clinical Remission at Week 6 and Week 52 | 5.4 (1.1 to 14.9) | 15.1 (8.9 to 23.4) | 16.7 (7.9 to 29.3) |
Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|
| Percentage of Participants Achieving Corticosteroid-free Remission at Week 52 | 8.3 (1.0 to 27.0) | 28.9 (16.4 to 44.3) | 28.6 (11.3 to 52.2) |
Collected over From first dose up to 18 weeks post last dose of study drug (Up to approximately 68 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vedolizumab IV 300 mg, Induction Phase Only | 0/167 (0%) | 17/167 (10.2%) | 34/167 (20.4%) |
| Maintenance Phase: Induction IV + Placebo | 0/56 (0%) | 6/56 (10.7%) | 31/56 (55.4%) |
| Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | 0/106 (0%) | 10/106 (9.4%) | 42/106 (39.6%) |
| Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | 0/54 (0%) | 7/54 (13%) | 31/54 (57.4%) |
| Event | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 12/167 | 5/56 | 3/106 | 1/54 |
| AnaemiaBlood and lymphatic system disorders | 2/167 | 1/56 | 2/106 | 0/54 |
| CholelithiasisHepatobiliary disorders | 0/167 | 0/56 | 0/106 | 1/54 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/167 | 0/56 | 0/106 | 1/54 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/167 | 0/56 | 0/106 | 1/54 |
| Scapula fractureInjury, poisoning and procedural complications | 0/167 | 0/56 | 0/106 | 1/54 |
| Ligament ruptureInjury, poisoning and procedural complications | 0/167 | 0/56 | 0/106 | 1/54 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/167 | 0/56 | 0/106 | 1/54 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/167 | 0/56 | 0/106 | 1/54 |
| Rib fractureInjury, poisoning and procedural complications | 0/167 | 0/56 | 0/106 | 1/54 |
| Event | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 7/167 | 14/56 | 12/106 | 5/54 |
| NasopharyngitisInfections and infestations | 4/167 | 11/56 | 11/106 | 10/54 |
| HeadacheNervous system disorders | 5/167 | 6/56 | 9/106 | 0/54 |
| Upper respiratory tract infectionInfections and infestations | 3/167 | 1/56 | 10/106 | 2/54 |
| AnaemiaBlood and lymphatic system disorders | 9/167 | 2/56 | 5/106 | 5/54 |
| Urinary tract infectionInfections and infestations | 5/167 | 2/56 | 0/106 | 4/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/167 | 1/56 | 6/106 | 4/54 |
| Alanine aminotransferase increasedInvestigations | 1/167 | 0/56 | 1/106 | 3/54 |
| Blood creatine phosphokinase increasedInvestigations | 0/167 | 0/56 | 1/106 | 3/54 |
| InsomniaPsychiatric disorders | 0/167 | 0/56 | 1/106 | 3/54 |
The safety analysis set included all participants who received at least 1 dose of vedolizumab IV.
| Age, Continuous(years) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| Mean | 42.7 (18 to 79) | 39.4 (21 to 66) | 38.1 (18 to 69) | 41.6 (18 to 68) | 40.79 (18 to 79) |
| Sex: Female, Male(Participants) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| Female | 79 | 22 | 41 | 23 | 165 |
| Male | 88 | 34 | 65 | 31 | 218 |
| Race/Ethnicity, Customized(Participants) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Non-Hispanic and Latino | 24 | 6 | 7 | 8 | 45 |
| Not Collected | 143 | 49 | 99 | 46 | 337 |
| Race/Ethnicity, Customized(Participants) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 0 | 0 | 3 |
| Asian | 39 | 13 | 14 | 5 | 71 |
| Black or African American | 1 | 0 | 0 | 2 | 3 |
| White | 125 | 42 | 92 | 47 | 306 |
| Region of Enrollment(Participants) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| Australia | 1 | 0 | 2 | 1 | 4 |
| Japan | 27 | 10 | 10 | 2 | 49 |
| Korea, Republic Of | 10 | 3 | 4 | 3 | 20 |
| Czech Republic | 2 | 3 | 10 | 4 | 19 |
| Hungary | 2 | 2 | 2 | 6 | 12 |
| Poland | 37 | 13 | 35 | 10 | 95 |
| Serbia | 1 | 1 | 0 | 1 | 3 |
| Slovakia | 3 | 0 | 4 | 3 | 10 |
| Bosnia | 0 | 0 | 2 | 0 | 2 |
| Bulgaria | 3 | 1 | 1 | 1 | 6 |
| Croatia | 8 | 1 | 0 | 1 | 10 |
| Estonia | 2 | 0 | 0 | 0 | 2 |
| Israel | 2 | 0 | 0 | 0 | 2 |
| Romania | 4 | 0 | 3 | 0 | 7 |
| Russia | 12 | 0 | 5 | 3 | 20 |
| Turkey | 1 | 2 | 0 | 0 | 3 |
| Ukraine | 11 | 4 | 6 | 2 | 23 |
| Canada | 4 | 3 | 2 | 2 | 11 |
| United States | 24 | 6 | 7 | 8 | 45 |
| Brazil | 4 | 0 | 3 | 1 | 8 |
| Mexico | 2 | 1 | 0 | 0 | 3 |
| Belgium | 0 | 2 | 0 | 0 | 2 |
| Denmark | 0 | 1 | 0 | 0 | 1 |
| Germany | 0 | 3 | 3 | 1 | 7 |
| Italy | 4 | 0 | 2 | 3 | 9 |
| Lithuania | 0 | 0 | 4 | 1 | 5 |
| Netherlands | 1 | 0 | 0 | 0 | 1 |
| Spain | 1 | 0 | 0 | 0 | 1 |
| United Kingdom | 1 | 0 | 1 | 1 | 3 |
| Height(cm) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| Mean | 169.3 (145 to 193) | 172.4 (147 to 194) | 171.9 (151 to 197) | 171.2 (152 to 196) | 170.7 (145 to 197) |
| Weight(kg) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| Mean | 68.20 (37.0 to 150.2) | 73.96 (40.6 to 160.0) | 71.58 (44.0 to 131.0) | 76.95 (50.6 to 124.8) | 71.21 (37.0 to 160.0) |
| Body Mass Index (BMI)(kg/m^2) | Vedolizumab IV 300 mg, Induction Phase Only | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Maintenance Phase: Induction IV + Vedolizumab 300 mg IV | Total |
|---|---|---|---|---|---|
| Mean | 23.65 (15.1 to 40.3) | 24.66 (14.1 to 51.1) | 24.07 (17.0 to 41.0) | 26.21 (16.3 to 35.3) | 24.28 (14.1 to 51.1) |
13 further baseline measures are reported on the registry.
Showing the first 100 of 174 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2015 to primary completion in May 2018, 29 months.
Results were first posted in Jan 2020, 1 year 7 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 29 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab